Menu
Not yet recruiting NCT07222813

Evaluation of Liver Stiffness Performance, by FibroScan®, to Detect Elevated Central Venous Pressure (CVP)

No phase Interventional Heart Failure Heart Failure - NYHA II - IV

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: FibroScan, Right-sided Heart Catheterization, Transthoracic echocardiography, Blood Sample Analysis.
Who it may be relevant to
Registry conditions: Heart Failure, Heart Failure - NYHA II - IV. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States, France, Germany, Poland
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Performance of Liver Stiffness Measurement (LSM) by FibroScan® for the Diagnosis of Elevated Central Venous Pressure (CVP)

Overview

This is a pivotal, global, prospective, cross-sectional, multicentric clinical investigation designed to explore a non-invasive, reliable alternative to invasive, catheter-based hemodynamic assessments, which are associated with procedural risks and limited applicability in certain participant populations.

Detailed description

CHF, as defined by the American College of Cardiology and the American Heart Association, is "a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood." These patients will often develop congestion that may require urgent hospitalization, especially if pulmonary congestion is present. However, congestion can be difficult to assess, especially when symptoms are mild, or in patients nearing discharge from an HF hospitalization.8 Increased cardiac filling pressures, including the CVP, often silently precede the appearance of congestive symptoms by days resulting in hepatic congestion.

Invasive methods, such as RHC, remain the gold standard method of measuring CVP, offering accurate and direct hemodynamic data. However, RHC requires specialized training and invasive vascular access and is associated with procedural risks including bleeding, infection, arrhythmia, and patient discomfort.

Echocardiography is the most common non-invasive adjunct tool for estimating CVP and assessing cardiac function. It evaluates indirect parameters, right atrial size, IVC diameter, and collapsibility to detect elevated CVP.

LSM by VCTE™ has emerged as a novel non-invasive approach to detecting elevated CVP indirectly. Liver elastography relies on imaging techniques to assess LSM, with high values equating to increased stiffness. While this was developed to assess fibrosis in chronic liver diseases, LSM also reflects increased CVP and hepatic congestion. Multiple studies have shown promising correlations between increased liver stiffness and invasively measured CVP, indicating a potential clinical strategy for detecting hemodynamic congestion non-invasively.

Given these considerations, the current clinical investigation aims to evaluate the 13.3 kPa cutoff performance of LSM with FibroScan (Echosens, Paris, France) to diagnose elevated CVP (\>10 mm Hg).

Interventions

  • Device FibroScan
    At Day 0: 1 FibroScan examination to collect Liver Stiffness Measurement (LSM)
  • Procedure Right-sided Heart Catheterization
    at Day 0: Right-sided Heart Catheterization (RHC) to measure Central Venous Pressure (CVP)
  • Procedure Transthoracic echocardiography
    at Day 0 assessment of cardiac function
  • Biological Blood Sample Analysis
    At Day0: To assess baseline organ function that may impact participant safety, and blood samples for clinical laboratory tests

Primary outcome measures

  • Proportion of individuals with elevated CVP (>10 mm Hg) who are correctly identified by LSM (cutoff of 13.3 kPa) [Sensitivity] [Time frame: at Day 0]
  • Proportion of individuals without elevated CVP (>10 mm Hg) who are correctly identified by LSM (cutoff of 13.3 kPa) [Specificity] [Time frame: at Day 0]
Secondary outcome measures (8)
  • Proportion of individuals correctly identified by LSM (Youden index) for the diagnosis of elevated CVP (>10 mm Hg) [Time frame: at Day 0]
  • Proportion of individuals correctly identified by LSM (Youden index) for the diagnosis of abnormal IVC diameter [Time frame: at Day 0]
  • Logistic regression model to identify clinical, laboratory, and echocardiographic factors associated with LSM/CVP discordance. [Time frame: at Day 0]
  • Correlation between LSM and echocardiographic parameters evaluated with Pearson or Spearman correlation coefficients [Time frame: at Day 0]
  • Correlation between LSM and NT-proBNP evaluated with Pearson or Spearman correlation coefficients [Time frame: at Day 0]
  • Correlation between LSM and CA-125 evaluated with Pearson or Spearman correlation coefficients [Time frame: at Day 0]
  • Correlation between LSM and clinical parameters evaluated with Pearson or Spearman correlation coefficients [Time frame: at Day 0]
  • Proportion of individuals correctly identified for the diagnosis of elevated CVP (>10 mm Hg) compared between LSM, echocardiography parameter and NT-proBNP using DeLong's test for correlated ROC curves [Time frame: at Day 0]

Eligibility criteria

Inclusion criteria

  • Have read, understood, and signed the informed consent form (ICF)
  • Be ≥18 years of age at the time of screening
  • Have suspected or diagnosed acute or chronic HF and be scheduled to undergo right-sided cardiac catheterization

Exclusion criteria

  • Inability to consent
  • Chronic liver disease (self-reported alcohol use >14 drinks/week in females and >21 drinks/week in males), positive hepatitis C virus serology, positive hepatitis B surface antigen, autoimmune hepatitis, hemochromatosis, or cholestatic disease)
  • BMI >40 kg/m2
  • Fontan-type circulation
  • Ascites
  • Heart transplantation
  • Pregnancy, breastfeeding, or intent to become pregnant during the study
  • Intent to donate/bank or retrieve eggs (ova, oocytes) or donate sperm during the study

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Diagnostic

Study locations

United States · 4 centers
  • Keck Medicine of USC-Norris Healthcare Center - Transplant Clinic — Los Angeles
  • University of Minnesota — Minneota
  • Medical University of South Carolina — Charleston
  • University of Texas Southwestern Medical Center - Clinical Heart and Vascular Center - Wes — Dallas
France · 1 center
  • Centre Hospitalier Universitaire (CHU) de Rennes - Hopital de Pontchaillou — Rennes
Germany · 1 center
  • Deutsches Herzzentrum der Charité (DHZC) - Klinik fuer Herz-, Thorax- und Gefaesschirurgie — Berlin
Poland · 1 center
  • Uniwersytet Medyczny im. Piastow Slaskich we Wroclawiu, Instytut Chorob Serca — Wroclaw

Identifiers

NCT: NCT07222813 · Cs002

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗